Finch Therapeutics Overview

  • Status
  • Public

  • Employees
  • 29

Employees

  • Stock Symbol
  • FNCH

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.51
  • (As of Monday Closing)

Finch Therapeutics General Information

Description

Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical date from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).

Contact Information

Formerly Known As
Finch Scientific, NextBiome
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
PINX
Corporate Office
  • 75 State Street
  • Suite 100
  • Boston, MA 02109
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Finch Therapeutics Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.51 $1.55 $0.80 - $9.42 $2.42M 1.61M 47.7K -$10.14

Finch Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 9,177 7,790 (9,952) 324,163
Revenue 0 107 861 18,532
EBITDA (17,512) (78,265) (109,391) (55,881)
Net Income (16,283) (74,754) (114,646) (58,160)
Total Assets 50,092 55,373 162,939 225,369
Total Debt 29,563 30,126 52,339 6,015
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Finch Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Finch Therapeutics‘s full profile, request access.

Request a free trial

Finch Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Finch Therapeutics‘s full profile, request access.

Request a free trial

Finch Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome
Drug Discovery
Boston, MA
29 As of 2023
00000
00000 0000-00-00
00000000 00000

000000

m, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo conse
0000000000000
Trevose, PA
00 As of 0000
00000
00000 0000-00-00
000000&0 00000

000

it in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sin
0000 000000000
San Francisco, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Finch Therapeutics Competitors (33)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Strongbridge Biopharma Corporate Backed or Acquired Trevose, PA 00 00000 000000&0 00000
Vir Formerly VC-backed San Francisco, CA 000 00000 00000000 00000
Seres Therapeutics Formerly VC-backed Cambridge, MA 000 00000 000000000 00000
CytomX Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
Vedanta Biosciences Venture Capital-Backed Cambridge, MA 000 00000 0000000000 00000
You’re viewing 5 of 33 competitors. Get the full list »

Finch Therapeutics Patents

Finch Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230201265-A1 Compositions comprising non-viable fecal microbiota and methods of use thereof Pending 31-Mar-2020 000000000
EP-4045630-A1 Compositions and methods for delivering a bacterial metabolite to a subject Inactive 18-Oct-2019 000000000
AU-2020366529-A1 Compositions and methods for delivering a bacterial metabolite to a subject Pending 18-Oct-2019 000000000
CA-3158132-A1 Compositions and methods for delivering a bacterial metabolite to a subject Pending 18-Oct-2019 000000000
US-20240131082-A1 Compositions and methods for delivering a bacterial metabolite to a subject Pending 18-Oct-2019 A61K35/74
To view Finch Therapeutics’s complete patent history, request access »

Finch Therapeutics Executive Team (21)

Name Title Board Seat
Matthew Blischak JD Chief Executive Officer & President
Lance Thibault Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Michelle Rose Chief Regulatory Officer
Bharat Dixit Vice President of Bioprocess and Analytical Development
Thomas Borody Ph.D Co-Founder
You’re viewing 5 of 21 executive team members. Get the full list »

Finch Therapeutics Board Members (9)

Name Representing Role Since
Chris Shumway Shumway Capital Board Member 000 0000
Domenic Ferrante Finch Therapeutics Board Member 000 0000
Jeffery Smisek JD Self Board Member 000 0000
Susan Graf Self Chairman & Board Member 000 0000
You’re viewing 4 of 9 board members. Get the full list »

Finch Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Finch Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Finch Therapeutics‘s full profile, request access.

Request a free trial

Finch Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Crestovo 23-Oct-2017 0000000000 Biotechnology 0000 0000
To view Finch Therapeutics’s complete acquisitions history, request access »

Finch Therapeutics ESG

Risk Overview

Risk Rating

Updated January, 10, 2023

21.5 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,638

Rank

00.0

Percentile

Healthcare

Industry

00 of 636

Rank

00.00

Percentile

Medical Services

Subindustry

00 of 115

Rank

00.00

Percentile

To view Finch Therapeutics’s complete esg history, request access »

Finch Therapeutics FAQs

  • Who is the founder of Finch Therapeutics?

    Mark Smith Ph.D, Andrew Noh, James Burgess, Zain Kassam MD, and Thomas Borody Ph.D are the founders of Finch Therapeutics.

  • Who is the CEO of Finch Therapeutics?

    Matthew Blischak JD is the CEO of Finch Therapeutics.

  • Where is Finch Therapeutics headquartered?

    Finch Therapeutics is headquartered in Boston, MA.

  • What is the size of Finch Therapeutics?

    Finch Therapeutics has 29 total employees.

  • What industry is Finch Therapeutics in?

    Finch Therapeutics’s primary industry is Drug Discovery.

  • Is Finch Therapeutics a private or public company?

    Finch Therapeutics is a Public company.

  • What is Finch Therapeutics’s stock symbol?

    The ticker symbol for Finch Therapeutics is FNCH.

  • What is the current stock price of Finch Therapeutics?

    As of 22-Jul-2024 the stock price of Finch Therapeutics is $1.51.

  • What is the current market cap of Finch Therapeutics?

    The current market capitalization of Finch Therapeutics is $2.42M.

  • Who are Finch Therapeutics’s competitors?

    Strongbridge Biopharma, Vir, Seres Therapeutics, CytomX Therapeutics, and Vedanta Biosciences are some of the 33 competitors of Finch Therapeutics.

  • What is Finch Therapeutics’s annual earnings per share (EPS)?

    Finch Therapeutics’s EPS for 12 months was -$10.14.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »